27511-79-1NC(=O)c1cn[nH]c1N.NC(=O)c1cn[nH]c1N.O=S(=O)(O)OUMPKASYMNORSRO-UHFFFAOYSA-N27511-79-1DTXSID90181933Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
Warning
H302+H312+H332 (50%): Harmful if swallowed, in contact with skin or if inhaled [Warning Acute toxicity, oral; acute toxicity, dermal; acute toxicity, inhalation]
P261, P264, P264+P265, P270, P271, P272, P273, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P317, P319, P321, P330, P332+P317, P333+P317, P337+P317, P362+P364, P391, P403+P233, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 4 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
REACH registered substance: 5-aminopyrazole-4-carboxamide hemisulphate (EC: 248-503-6)
1H-Pyrazole-4-carboxamide, 3-amino-, sulfate (2:1): Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.
UsesAllopurinol (A547300) impurity. A pyrazole derivative that has been shown to induce neoplasm immunogenicity.
Uses3-Amino-4-pyrazolecarboxamide hemisulfate salt was used to prepare 3-carbamoyl derivatives.
UsesReactant involved in synthesis of:Triazines and their phosphorus analogsPyrazolo[3,4-d]pyrimidines for use as cyclin-dependent kinase 2 inhibitors
General DescriptionPharmaceutical secondary standards for application in quality control provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards
Loading…
Loading…
No reaction records under the current filter.
Loading…